EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

Shen Qu, Weili Jia iD, Ye Nie, Wen Shi, Chao Chen, Zihao Zhao, Wenjie Song

Biomolecules · 2024

DOI: 10.3390/biom14070743 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Shen Qu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Xi'an Medical University, Xi'an 710021, China. Hauptthemen laut MEDLINE: Mucoproteins, Pancreatic Neoplasms, Oncogene Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wenjie Song, Special Support Program for High-level Talents in Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The anterior gradient protein 2 (AGR2) plays a crucial role in facilitating the formation of protein disulfide bonds within the endoplasmic reticulum (ER). Research suggests that AGR2 can function as an oncogene, with its heightened expression linked to the advancement of hepatobiliary and pancreatic cancers through invasion and metastasis. Notably, AGR2 not only serves as a pro-oncogenic agent but also as a downstream targeting protein, indirectly fostering cancer progression. This comprehensive review delves into the established functions and expression patterns of AGR2, emphasizing its pivotal role in cancer progression, particularly in hepatobiliary and pancreatic malignancies. Furthermore, AGR2 emerges as a potential cancer prognostic marker and a promising target for immunotherapy, offering novel avenues for the treatment of hepatobiliary and pancreatic cancers and enhancing patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucoproteinsPancreatic NeoplasmsOncogene ProteinsHumansLiver NeoplasmsAnimalsBiliary Tract NeoplasmsGene Expression Regulation, NeoplasticBiomarkers, Tumor

Stichwörter der Autor:innen

AGR2cancer invasion and prognosisendoplasmic reticulum stress (ERS)hepatobiliary and pancreatic cancerimmunotherapy

Substanzen

MucoproteinsAGR2 protein, humanOncogene ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Xi'an Medical University, Xi'an 710021, China.
  • Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.

ORCID-Profile: Weili Jia

Förderung

  • Wenjie Song
  • Special Support Program for High-level Talents in Shaanxi Province

Zitieren

APA

Qu, S., Jia, W., Nie, Y., Shi, W., Chen, C., Zhao, Z., & Song, W. (2024). AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment. Biomolecules. https://doi.org/10.3390/biom14070743

Vancouver

Qu S, Jia W, Nie Y, Shi W, Chen C, Zhao Z, et al. AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment. Biomolecules. 2024. doi:10.3390/biom14070743

BibTeX
@article{Qu2024,
  author = {Qu, Shen and Jia, Weili and Nie, Ye and Shi, Wen and Chen, Chao and Zhao, Zihao and Song, Wenjie},
  title = {AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14070743}
}
Kostenlos starten →